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The therapeutic experience reported in the paper was con-
ceived after the use of nimotuzumab and radiotherapy 
(BSCPED-05 international multicentric trial, EUDRACT 
2005-003100-11) in 2009 when we decided to explore the 
activity of the same combination plus vinorelbine (see the 
paper for the rationale).
The company developing nimotuzumab in Europe 
agreed for its compassionate use in DIPG patients in this 
context.
The Ethical Committee (EC) of our Institution (Fon-
dazione IRCCS Istituto Nazionale dei Tumori, in Milan) 
approved any single patient-case admission to the compas-
sionate use of the combination of nimotuzumab with vinorel-
bine and radiotherapy, according to the procedure designed 
by the Italian Ministry of Health and by the national Agency 
for Drug Evaluation (AIFA).
The signed informed consent, approved by the EC, 
included the possibility of collecting and publishing data, 
according to the law, in an observational report.
Meanwhile, after some time (February 2012), an ancil-
lary biological study on the same cohort of patients was in 
fact approved by the Ethical Committee also concerning the 
analysis of blood samples for biological research.
The original article can be found online at https ://doi.org/10.1007/
s1106 0-014-1428-z.
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In conclusion, our paper was a report of the clinical data 
from a cohort of patients treated in the context of a compas-
sionate use approved as such.
As to the paper writing, we adopt a post-hoc analysis as 
a phase 2 study but we acknowledge as an ERRATUM that 
this was not a formal phase 2 study.
